Company intelligence / Profile preview

Heron Opto

San Diego, California, United States

Ownership: Private
Employees: ~170
Development stage: Other

Overview

Heron Therapeutics is commercially focused, with approved products including ZYNRELEF (for post-op pain), CINVANTI (for CINV), APONVIE (for PONV), and SUSTOL (for CINV); 2024 revenue exceeded $144 million. Products are seeing increased adoption, particularly ZYNRELEF and APONVIE.

Therapeutic areas: OncologyNeurologyGastroenterology
Modalities: Small moleculeBiologic
Industry: Biotech

Partnerships

CrossLink partnership for salescommercial relationships with hospitals/ASCs

Beyond the preview

Go deeper on Heron Opto.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Heron Opto.

Explore the full profile